AstraZeneca's Farxiga fails to get U.S. approval for Type-1 diabetes
British drugmaker AstraZeneca Plc said on Monday the U.S. Food and Drug Administration declined to approve its diabetes treatment, Farxiga, for use as a supplement to insulin in adults with a rare-type of the condition.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: AstraZeneca | Diabetes | Diabetes Type 1 | Endocrinology | Food and Drug Administration (FDA) | Health | Insulin | UK Health